サンプル依頼リスト カート
  • English
  • Korean
表紙：掌蹠膿疱症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1374834

掌蹠膿疱症治療の世界市場-2023年～2030年

Global Palmoplantar Pustulosis Treatment Market - 2023-2030

出版日
ページ情報
英文 187 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
掌蹠膿疱症治療の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

掌蹠膿疱症は、手足に生じる乾癬の一種です。鱗屑、カサカサした変色した皮膚の斑点が生じます。症状は、手および足の上面、底面、手指および足指の間の皮膚に発現します。掌蹠膿疱症は自己炎症性皮膚疾患ですが、正確な原因はまだ完全には解明されていません。掌蹠膿疱症は家族性に発症することがあり、成人前に発症することはまれです。喫煙者は特にこのタイプの乾癬になりやすいようです。

また、乾癬の治療法はありませんが、症状を抑えるための治療法はあります。水疱を縮小させるためにステロイド外用薬などを直接塗布し、皮膚を保湿するためにサリチル酸軟膏や尿素クリームなどのエモリエント剤を使用するのが一般的で、レチノイド薬や光線療法も行われ、重症の場合はメトトレキサートやシクロスポリンなどの免疫抑制剤を使用するのが一般的です。これらの薬剤が耐えられない、あるいは効果がない場合は、エタネルセプトやアダリムマブなどのTNFα遮断薬、ウステキヌマブなどの抗IL-12/23阻害薬、グセルクマブを中心とする抗IL-23阻害薬、抗IL-17などの生物学的製剤が処方されます。

市場力学：促進要因

新規・先進治療薬に対する需要の増加

新規・先進治療薬に対する需要の増加は、予測期間を通じて市場を牽引すると予想されます。新規治療薬は、掌蹠膿疱症の症状管理に関連するアンメットニーズに対応することを目的としており、より良い疾患管理のための代替的または補完的な治療選択肢を提供します。多くの製薬企業が、高度な治療効果を持つ新規治療薬の開発に注力しています。

例えば、2023年8月23日、協和キリン株式会社は、既存治療で効果不十分な掌蹠膿疱症を適応症とするルミセフ（一般名：ブロダルマブ）の一部変更承認を厚生労働省から取得したと発表しました。

ルミセフは、完全ヒト型抗インターロイキン17（IL-17）受容体A抗体で、IL-17A受容体に選択的に結合することにより、IL-17A、IL-17A/F、IL-17F、IL-17Cなどの炎症性サイトカインの生物学的活性を阻害します。ルミセフは、掌蹠膿疱症で承認された初めてのIL-17経路阻害剤です。

さらに、FDA承認などの規制当局の承認は、新規の先端治療薬の開発に対する患者の信頼を高めます。例えば、2021年12月15日、ベーリンガーインゲルハイムは、米国食品医薬品局（FDA）が汎発性膿疱性乾癬再燃の治療薬としてスペソリマブの生物製剤承認申請（BLA）を受理し、優先審査権を付与したことを明らかにしました。

さらに、掌蹠膿疱症の有病率の増加、革新的な薬剤に対するFDA承認の増加、臨床試験の増加、新規治療法の開発に対する認識と進歩の増加、光線療法の技術的進歩は、予測期間中に市場を牽引すると予想される要因です。

阻害要因

ステロイド外用薬やその他の薬剤に伴う合併症や副作用、光線療法にかかる高額な費用、光線療法に伴うリスク、より優れた迅速な治療法の欠如などの要因が、市場の阻害要因になると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 新規・先端治療薬に対する需要の増加
    • 抑制要因
      • ステロイド外用剤の使用に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • 特許分析
  • ボリューム分析
  • DMIオピニオン

第6章 COVID-19分析

第7章 治療タイプ別

  • 局所ステロイドまたはカルシポトリエンクリーム
  • エモリエント剤
    • サリチル酸軟膏
    • 尿素クリーム
    • ヒールバーム
    • その他
  • レチノイド薬
    • アシトレチン
    • レチノール
    • ベキサロテン
    • アリトレチノイン
    • その他
  • 免疫抑制剤
    • メトトレキサート
    • シクロスポリン
    • その他
  • 生物製剤
    • TNFα遮断薬
      • エタネルセプト
      • アダリムマブ
      • その他
    • 抗インターロイキン薬
      • ウステキヌマブ
      • グセルクマブ
      • その他
  • テトラサイクリン系抗生物質
  • 光線療法
    • ナローバンドUVB
    • 光化学療法
    • PUVA
  • その他

第8章 投与経路別

  • 経口
  • 局所
  • 静脈内投与
  • その他

第9章 販売チャネル別

  • 販売チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • エンドユーザー
    • 病院
    • 皮膚科クリニック
    • 光線療法センター
    • 学術研究機関
    • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Teva Pharmaceuticals USA, Inc.
  • Pfizer Inc.
  • Kyowa Kirin Co., Ltd.
  • Novartis AG
  • Amgen Inc.
  • Janssen Biotech, Inc.
  • AdvaCare Pharma
  • Palsons Derma Pvt Ltd
  • SiNi Pharma Pvt Ltd

第13章 付録

目次
Product Code: PH7364

Overview

Palmoplantar psoriasis is a type of psoriasis on the hands and feet. It causes patches of scaly, flaky, discolored skin. Symptoms can affect the skin on the top and bottom of the hands and feet, as well as on and in between the fingers and toes. Palmoplantar pustulosis is an auto-inflammatory skin disease but the exact cause of the condition is still not fully understood. It sometimes runs in families and rarely occurs before adulthood. Smokers seem to be especially prone to this type of psoriasis.

Moreover, there isn't a cure for psoriasis, but treatment is available to help manage the symptoms. Medications such as topical steroids are applied directly to reduce the blisters, emollients such as salicylic acid ointment and urea cream are most commonly used to moisturize the skin, retinoid medications, and phototherapy are also used, and in severe cases, immunosuppressants like methotrexate or cyclosporine are commonly used. If these medications are not tolerated or are inefficient, biologicals like TNF-alpha blockers such as etanercept and adalimumab, anti-IL-12/23 inhibitors such as ustekinumab, anti-IL-23 inhibitors mainly guselkumab and anti-IL-17 are prescribed.

Market Dynamics: Drivers

Increasing demand for novel and advanced therapeutics

The increasing demand for novel and advanced therapeutics is expected to drive the market over the forecast period. The novel therapeutics aim to address the unmet needs associated with the management of symptoms of palmoplantar pustulosis by providing alternative or complementary treatment options for better disease management. Many pharmaceutical companies are focusing on the development of novel therapeutics with advanced outcomes.

For instance, on August 23, 2023, Kyowa Kirin Co., Ltd. Released that the company has received approval from the Ministry of Health, Labour and Welfare (MHLW) for partial change of approved indication of LUMICEF (brodalumab) for the treatment of palmoplantar pustulosis that respond inadequately to existing therapies.

LUMICEF is a fully human anti-interleukin-17 (IL-17) receptor A antibody that inhibits the biological activity of inflammatory cytokines such as IL-17A, IL-17A/F, IL-17F and IL-17C by binding to IL-17A receptor selectively. LUMICEF is the first IL-17 pathway inhibitor approved for palmoplantar pustulosis.

In Addition, regulatory approvals such as FDA approvals increase the trust in patients about the development of novel advanced therapeutics. For instance, on December 15, 2021, Boehringer Ingelheim cleared that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for spesolimab for the treatment of generalized pustular psoriasis flares.

Further, the increasing prevalence of palmoplantar pustulosis, rising FDA approvals for innovative drugs, increasing clinical trials, increasing awareness and advancements in the development of novel therapies and technological advancements in phototherapy are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with topical steroids and other drugs, the high cost of the phototherapy treatment, risks associated with phototherapy and lack of better and quick treatment are expected to hamper the market.

Segment Analysis

The global palmoplantar pustulosis treatment market is segmented based on treatment type, route of administration, sales channel and region.

The topical steroids segment accounted for approximately 52.4% of the palmoplantar pustulosis treatment market share

The topical steroids segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for this disease, but topical steroids are considered first-line therapeutics for the management of palmoplantar pustulosis. These medications, also known as topical corticosteroids, are applied directly to the affected skin to help reduce inflammation and alleviate symptoms such as redness, itching, and the formation of pustules.

Moreover, topical steroids work by suppressing the immune response and reducing inflammation. In palmoplantar pustulosis, where inflammation plays a significant role in the development of pustules, these medications can help manage symptoms and severity. Topical steroids come in varying strengths, and the choice of strength depends on the severity of the condition and the affected areas. Short-term use of high-potency steroids may be necessary for acute flare-ups, while lower-potency options are often used for maintenance therapy.

Further, their wide availability, acceptability, and, ease of application helps to hold the largest market share. In some cases, topical steroids may be used in combination with other topical agents or systemic medications to enhance therapeutic effects and manage the condition comprehensively. In addition, their wide adoption also increases the demand for the topical steroids.

Geographical Analysis

North America accounted for approximately 41.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing R&D activities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, leads to the launch of novel therapeutics and alternative treatment options for better patient outcomes.

For instance, on March 08, 2021, AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, released that top-line data from its Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe palmoplantar pustulosis (PPP).

Furthermore, the region has a strong presence of pharmaceutical companies engaged in research and development. New and innovative treatments may be more readily available in North America. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.

Competitive Landscape

The major global players in the palmoplantar pustulosis treatment market include: F. Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Kyowa Kirin Co., Ltd., Novartis AG, Amgen Inc., Janssen Biotech, Inc., AdvaCare Pharma, Palsons Derma Pvt Ltd and SiNi Pharma Pvt Ltd. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global palmoplantar pustulosis treatment market. The pandemic created unprecedented challenges for pharmaceutical industries worldwide, including the global palmoplantar pustulosis treatment market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic and its related restrictions. The pandemic also disrupted the supply chain of these treatment medications globally.

Market Segmentation

By Treatment Type

  • Topical Steroids or Calcipotriene Creams
  • Emollients
    • Salicylic Acid Ointment
    • Urea Cream
    • Heel Balm
    • Others
  • Retinoid Medications
    • Acitretin
    • Retinol
    • Bexarotene
    • Alitretinoin
    • Others
  • Immunosuppressants
    • Methotrexate
    • Cyclosporine
    • Others
  • Biologics
    • TNF-Alpha Blockers
  • Etanercept
  • Adalimumab
  • Others
    • Anti Interleukin Inhibitors
  • Ustekinumab
  • Guselkumab
  • Others
  • Tetracycline Antibiotics
  • Phototherapy
    • Narrowband UVB
    • Photochemotherapy
    • PUVA
  • Others

By Route Of Administration

  • Oral
  • Topical
  • Intravenous
  • Others

By Sales Channel

  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End-User
    • Hospitals
    • Dermatology Clinics
    • Phototherapy Centers
    • Academic and Research Institutes
    • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global palmoplantar pustulosis treatment market segmentation based on treatment type, route of administration, sales channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of palmoplantar pustulosis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global palmoplantar pustulosis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Novel and Advanced Therapeutics
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Use of Topical Steroids
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. Volume Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Topical Steroids or Calcipotriene Creams*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Emollients
    • 7.3.1. Salicylic Acid Ointment
    • 7.3.2. Urea Cream
    • 7.3.3. Heel Balm
    • 7.3.4. Others
  • 7.4. Retinoid Medications
    • 7.4.1. Acitretin
    • 7.4.2. Retinol
    • 7.4.3. Bexarotene
    • 7.4.4. Alitretinoin
    • 7.4.5. Others
  • 7.5. Immunosuppressants
    • 7.5.1. Methotrexate
    • 7.5.2. Cyclosporine
    • 7.5.3. Others
  • 7.6. Biologics
    • 7.6.1. TNF-Alpha Blockers
      • 7.6.1.1. Etanercept
      • 7.6.1.2. Adalimumab
      • 7.6.1.3. Others
    • 7.6.2. Anti Interleukin Inhibitors
      • 7.6.2.1. Ustekinumab
      • 7.6.2.2. Guselkumab
      • 7.6.2.3. Others
  • 7.7. Tetracycline Antibiotics
  • 7.8. Phototherapy
    • 7.8.1. Narrowband UVB
    • 7.8.2. Photochemotherapy
    • 7.8.3. PUVA
  • 7.9. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Topical
  • 8.4. Intravenous
  • 8.5. Others

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. Distribution Channel*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Hospital Pharmacies
    • 9.2.4. Retail Pharmacies
    • 9.2.5. Online Pharmacies
  • 9.3. End-User
    • 9.3.1. Hospitals
    • 9.3.2. Dermatology Clinics
    • 9.3.3. Phototherapy Centers
    • 9.3.4. Academic and Research Institutes
    • 9.3.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Teva Pharmaceuticals USA, Inc.
  • 12.3. Pfizer Inc.
  • 12.4. Kyowa Kirin Co., Ltd.
  • 12.5. Novartis AG
  • 12.6. Amgen Inc.
  • 12.7. Janssen Biotech, Inc.
  • 12.8. AdvaCare Pharma
  • 12.9. Palsons Derma Pvt Ltd
  • 12.10. SiNi Pharma Pvt Ltd

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us